Clinical trial MIDAS
MInimal residual Disease Adapted Strategy: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group (IFM) (MIDAS ; IFM2020-02)
| Cancers | |
|---|---|
| Organ | Myeloma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Oui |
| Sponsor | IFM |
| EudraCT Identifier | 2020-005216-21 |
| Inclusion criteria | Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation |
| Last update |